Repertoire Immune Medicines expanded its partner roster with Eli Lilly in a collaboration to develop tolerizing therapies for autoimmune diseases, securing an up‑front payment and potential milestones pushing the deal toward roughly $1.8–1.9 billion. The agreement builds on Repertoire’s Decode immune‑profiling platform and follows prior alliances with Bristol Myers Squibb and Genentech. Repertoire will apply its single‑cell and repertoire mapping technology to identify tolerizing vaccine candidates and markers of immune state; Lilly will fund development and commercial programs. Repertoire leaders framed the deal as external validation of their platform’s ability to translate immune‑decoding into therapeutic candidates. The transaction emphasizes big‑pharma appetite for platform companies that can stratify immune biology and generate de‑risked preclinical assets for difficult autoimmune indications.